(CLARI) Clariane SE - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: PA (France) | Market Cap: 1.518m EUR | Total Return: 8.6% in 12m
Nursing Homes, Healthcare Clinics, Assisted Living, Home Care
Total Rating 45
Safety 69
Buy Signal -0.37
Medical Care Facilities
Industry Rotation: +12.5
Industry Rotation: +12.5
Market Cap:
1.76B
Avg Turnover: 1.45M
Avg Turnover: 1.45M
Risk 3d forecast
Volatility47.7%
VaR 5th Pctl7.56%
VaR vs Median-4.54%
Reward TTM
Sharpe Ratio0.40
Rel. Str. IBD48.9
Rel. Str. Peer Group63.9
Character TTM
Beta-0.227
Beta Downside-0.839
Hurst Exponent0.541
Drawdowns 3y
Max DD81.31%
CAGR/Max DD-0.03
CAGR/Mean DD-0.06
EPS (Earnings per Share)
EPS CAGR: 0.00%
EPS Trend: -41.3%
EPS Trend: -41.3%
Last SUE: 0.00
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 6.35%
Rev. Trend: 34.6%
Rev. Trend: 34.6%
Last SUE: -0.06
Qual. Beats: 0
Qual. Beats: 0
Warnings
Share dilution 144.5% YoY
High Debt/EBITDA (5.3) with thin interest coverage (0.4)
Interest Coverage Ratio 0.4 is critical
Altman Z'' 0.47 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Description: CLARI Clariane SE
Clariane SE, formerly known as Korian, is a Paris-based healthcare provider operating across six European markets, including France, Germany, and the United Kingdom. The company manages a diversified portfolio consisting of long-term nursing homes, post-acute and rehabilitation clinics, mental health facilities, and specialized medical-surgery-obstetrics centers. Its business model integrates traditional inpatient hospitalization with flexible outpatient diagnostics and alternative senior living solutions like shared housing and domiciliary care.
The European elderly care sector is currently shaped by high barriers to entry due to stringent regional regulations and an increasing demand for specialized dementia and mental health services. As an operator in the Health Care Facilities sub-industry, Clariane relies on a mix of public funding and private pay models to sustain its capital-intensive infrastructure. Investors looking for deeper financial metrics should evaluate the companys performance data on ValueRay.
- Asset disposal program execution determines debt reduction and liquidity stability
- Occupancy rate recovery in European nursing homes drives organic revenue growth
- Rising labor costs and nurse shortages pressure operating margins across core markets
- Regulatory scrutiny of private elderly care providers impacts long-term valuation multiples
- Interest rate fluctuations influence refinancing costs for heavy real estate debt load
Piotroski VR‑10 (Strict)
3.5
| Net Income: -12.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 4.60 > 1.0 |
| NWC/Revenue: -7.79% < 20% (prev -16.91%; Δ 9.12% < -1%) |
| CFO/TA 0.10 > 3% & CFO 1.41b > Net Income -12.2m |
| Net Debt (10.57b) to EBITDA (2.00b): 5.29 < 3 |
| Current Ratio: 0.70 > 1.5 & < 3 |
| Outstanding Shares: last fiscal year (355.6m) vs prev 53.66% < -2% |
| Gross Margin: 16.01% > 18% (prev 0.21%; Δ 1.58k% > 0.5%) |
| Asset Turnover: 65.23% > 50% (prev 52.25%; Δ 12.98% > 0%) |
| Interest Coverage Ratio: 0.43 > 6 (EBITDA TTM 2.00b / Interest Expense TTM 489.1m) |
Altman Z''
0.47
| A: -0.05 (Total Current Assets 1.69b - Total Current Liabilities 2.42b) / Total Assets 13.81b |
| B: 0.15 (Retained Earnings 2.10b / Total Assets 13.81b) |
| C: 0.01 (EBIT TTM 212.1m / Avg Total Assets 14.21b) |
| D: 0.21 (Book Value of Equity 2.10b / Total Liabilities 9.89b) |
| Altman-Z'' Score: 0.47 = B |
Beneish M
-3.06
| DSRI: 0.56 (Receivables 419.2m/619.0m, Revenue 9.27b/7.64b) |
| GMI: 1.29 (GM 16.01% / 20.70%) |
| AQI: 1.02 (AQ_t 0.41 / AQ_t-1 0.40) |
| SGI: 1.21 (Revenue 9.27b / 7.64b) |
| TATA: -0.10 (NI -12.2m - CFO 1.41b) / TA 13.81b) |
| Beneish M-Score: -3.06 (Cap -4..+1) = AA |
What is the price of CLARI shares?
As of May 20, 2026, the stock is trading at EUR 4.11 with a total of 188,775 shares traded.
Over the past week, the price has changed by -0.39%, over one month by +9.41%, over three months by +8.55% and over the past year by +8.55%.
Over the past week, the price has changed by -0.39%, over one month by +9.41%, over three months by +8.55% and over the past year by +8.55%.
Is CLARI a buy, sell or hold?
Clariane SE has no consensus analysts rating.
What are the forecasts/targets for the CLARI price?
| Analysts Target Price | - | - |
Clariane SE (CLARI) - Fundamental Data Overview
as of 18 May 2026
Market Cap USD = 1.76b (1.52b EUR * 1.1626 EUR.USD)P/E Forward = 36.1011
P/S = 0.2859
P/B = 0.4234
P/EG = 0.7848
Revenue TTM = 9.27b EUR
EBIT TTM = 212.1m EUR
EBITDA TTM = 2.00b EUR
Long Term Debt = 1.81b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.03b EUR (from shortTermDebt, last quarter)
Debt = 11.36b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.57b EUR (from netDebt column, last quarter)
Enterprise Value = 12.75b EUR (1.52b + Debt 11.36b - CCE 121.2m)
Interest Coverage Ratio = 0.43 (Ebit TTM 212.1m / Interest Expense TTM 489.1m)
EV/FCF = 11.97x (Enterprise Value 12.75b / FCF TTM 1.07b)
FCF Yield = 8.35% (FCF TTM 1.07b / Enterprise Value 12.75b)
FCF Margin = 11.49% (FCF TTM 1.07b / Revenue TTM 9.27b)
Net Margin = -0.13% (Net Income TTM -12.2m / Revenue TTM 9.27b)
Gross Margin = 16.01% ((Revenue TTM 9.27b - Cost of Revenue TTM 7.79b) / Revenue TTM)
Gross Margin QoQ = -2.76% (prev 30.56%)
Tobins Q-Ratio = 0.92 (Enterprise Value 12.75b / Total Assets 13.81b)
Interest Expense / Debt = 1.34% (Interest Expense 152.7m / Debt 11.36b)
Taxrate = 17.39% (13.1m / 75.3m)
NOPAT = 175.2m (EBIT 212.1m * (1 - 17.39%))
Current Ratio = 0.70 (Total Current Assets 1.69b / Total Current Liabilities 2.42b)
Debt / Equity = 3.14 (Debt 11.36b / totalStockholderEquity, last quarter 3.61b)
Debt / EBITDA = 5.29 (Net Debt 10.57b / EBITDA 2.00b)
Debt / FCF = 9.93 (Net Debt 10.57b / FCF TTM 1.07b)
Total Stockholder Equity = 3.59b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.09% (Net Income -12.2m / Total Assets 13.81b)
RoE = -0.34% (Net Income TTM -12.2m / Total Stockholder Equity 3.59b)
RoCE = 3.93% (EBIT 212.1m / Capital Employed (Equity 3.59b + L.T.Debt 1.81b))
RoIC = 2.39% (NOPAT 175.2m / Invested Capital 7.32b)
WACC = 1.59% (E(1.52b)/V(12.88b) * Re(5.18%) + D(11.36b)/V(12.88b) * Rd(1.34%) * (1-Tc(0.17)))
Discount Rate = 5.18% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: 59.81 | Cagr: 61.08%
[DCF] Terminal Value 87.44% ; FCFF base≈821.2m ; Y1≈924.5m ; Y5≈1.24b
[DCF] Fair Price = 72.67 (EV 36.48b - Net Debt 10.57b = Equity 25.91b / Shares 356.5m; r=6.0% [WACC]; 5y FCF grow 14.61% → 3.0% )
EPS Correlation: -41.30 | EPS CAGR: 0.0% | SUE: 0.0 | # QB: 0
Revenue Correlation: 34.57 | Revenue CAGR: 6.35% | SUE: -0.06 | # QB: 0
EPS current Year (2026-12-31): EPS=0.07 | Chg30d=-71.16% | Revisions=+20% | GrowthEPS=+1622.5% | GrowthRev=+2.0%
EPS next Year (2027-12-31): EPS=0.31 | Chg30d=-6.97% | Revisions=N/A | GrowthEPS=+81.5% | GrowthRev=+4.7%
[Analyst] Revisions Ratio: +20%